# Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

> **NCT05668754** · PHASE2 · COMPLETED · sponsor: **Zevra Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Idiopathic Hypersomnia

## Interventions

- **DRUG:** Serdexmethylphenidate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05668754
- **Lead sponsor:** Zevra Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-28
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-03-21
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668754, "Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05668754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*